Back to Agenda
Parallel Session 5B: Rare Diseases
Session Chair(s)
Yazeed AlRuthia
Professor, Department of Clinical Pharmacy
King Saud University, College of Pharmacy, Saudi Arabia
Niveen Osman, MBA
Regulatory Affairs Director
Amgen Inc., United Arab Emirates
The regulation and treatment of rare diseases have become a growing priority in the MENA region, where limited access to orphan drugs can create challenges for patient access. This session will focus on advancing regulatory and strategic plans for rare diseases and orphan drugs in the MENA region, with key insights from the Saudi FDA, experiences from national health systems, and international best practices.
Speaker(s)
Patient Access to Orphan Drugs in European National Health Systems: Learned Lessons
Virginie Hivert, PharmD, PhD
Eurordis-Rare Diseases Europe, France
Therapeutic Development Director
Patient-Centric Care for Rare Diseases
Eric Obscherning
Access Partnership, United States
Director, Health & Life Sciences
Maurille Feudjo Tepie
UCB, United Kingdom
VP & Head, GLobal RWE and Digital Sciences
Panel Discussion with QandA
Marco Rafael, PharmD, MBA, RPh
Roche, Switzerland
Regulatory Policy Lead
Panel Discussion with QandA
Kristina Larsson, MS
European Medicines Agency, Netherlands
Head of Orphan Medicines, Division for Human Medicines Evidence Generation
Panel Discussion with QandA
Abeer Elbehairy
Egyptian Drug Authority (EDA), Egypt
General Manager - Drug Utilization & Pharmacy Practice G.A
Have an account?